Key Stats for Novo Nordisk Stock
- Price change for Novo Nordisk stock Today: 1%
- $NVO Stock Price as of Apr. 2: $37
- 52-Week High: $81
- $NVO Stock Price Target: $47
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Novo Nordisk (NVO) stock got a boost on Thursday after the company released data showing its Wegovy pill outperformed Eli Lilly’s newly approved weight-loss pill in a cross-trial comparison.
- The study compared oral Wegovy — which contains semaglutide — against Lilly’s orforglipron, now branded as Foundayo.
- The results showed Wegovy produced greater average weight loss: 16.6% versus 12.4% for Foundayo.
- Patients on Wegovy were also far less likely to stop treatment due to side effects.
- According to the data, Foundayo was associated with about 14 times higher odds of quitting due to side effects.
It’s worth noting this wasn’t a head-to-head trial.
Novo analyzed data from previously published studies rather than running fresh clinical tests.
Still, the company says the findings add to a growing body of evidence supporting semaglutide’s clinical profile.
A separate analysis found that 84% of patients preferred a drug profile like Wegovy’s over Foundayo’s.
Novo will present more details at the Obesity Medicine Association’s annual conference next week.
- The two companies are now locked in a battle to win over doctors, patients, and payers.
- Lilly has leaned into convenience — Foundayo has no food restrictions, while the Wegovy pill must be taken on an empty stomach first thing in the morning with limited water and a 30-minute wait before eating.
- Novo CEO Mike Doustdar has pushed back, arguing that patients care most about efficacy.
Since launching in the U.S. in January, over 600,000 patients have started taking the Wegovy pill. Analysts have called it one of the best drug launches in recent memory.
See analysts’ growth forecasts and price targets for Novo Nordisk stock (It’s free) >>>
What the Market Is Telling Us About Novo Nordisk Stock
The data is a welcome development for Novo Nordisk stock, which has had a rough stretch.
The company is navigating pricing pressure, a soft 2026 guidance, and Lilly’s growing market presence — all of which have weighed on sentiment.
That said, some analysts note that new Wegovy pill prescriptions may be slowing as doctors wait to see how Foundayo performs.
Barclays called this “patient warehousing,” suggesting some physicians are holding off until Foundayo launches before committing.
Expectations for Foundayo have already been sharply trimmed, from around $4 billion in projected 2026 sales to $1.6 billion.
HSBC has gone further, recommending clients sell Lilly stock and cautioning that Foundayo’s expectations remain overblown.
For Novo Nordisk stock, the next few weeks could be pivotal.
How quickly Foundayo gains traction — or doesn’t — may be the single biggest factor driving the share price in the near term.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Novo Nordisk Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
